Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells

Experimental Cell Research

Volumn 316, Issue 14, 2010, Pages 2251-2259

  Chi, Xiuling ^a   Tai, Hsin Hsiung ^a  

^a University of Kentucky   (United States)

Author keywords

15 PGDH; COX 2; Interleukin 4; Lung cancer; Prostaglandins

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; GELATINASE B; INTERLEUKIN 4; JANUS KINASE; KAEMPFEROL; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; STAT6 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER CELL; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 77954383313     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.06.001     Document Type: Article

References (52)

1. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69:145-182.
2. Jakobsson P.J., Thorén S., Morgenstern R., Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:220-225.
3. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:483-493.
4. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2003, 24:96-102.
5. Yoshimatsu K., Altorki N.K., Golijanin D., Zhang F., Jakobsson P.J., Dannenberg A.J., Subbaramaiah K. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 2001, 7:2669-2674.
6. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005, 26:65-72.
7. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L., Katkuri S., DuBois R.N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 2005, 280:3217-3223.
8. Yan M., Rerko R.M., Platzer P., Dawson D., Willis J., Tong M., Lawrence E., Lutterbaugh J., Lu S., Willson J.K., Luo G., Hensold J., Tai H.H., Wilson K., Markowitz S.D. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17468-17473.
9. Wolf I., O'Kelly J., Rubinek T., Tong M., Nguyen A., Lin B.T., Tai H.H., Karlan B.Y., Koeffler H.P. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006, 66:7818-7823.
10. Tong M., Tai H.H. Induction of NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase expression by androgens in human prostate cancer cells. Biochem. Biophys. Res. Commun. 2000, 276:77-81.
11. Frenkian M., Segond N., Pidoux E., Cohen R., Jullienne A. Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins Other Lipid Mediat. 2001, 65:11-20.
12. Tong M., Tai H.H. 15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other Arch glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells. Arch. Biochem. Biophys. 2005, 435:50-55.
13. Tong M., Ding Y., Tai H.H. Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem. Pharmacol. 2006, 72:701-709.
14. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65:7917-7925.
15. Wakimoto N., Wolf I., Yin D., O'Kelly J., Akagi T., Abramovitz L., Black K.L., Tai H.H., Koeffler H.P. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res. 2008, 68:6978-6986.
16. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 1999, 17:701-738.
17. Haque S.J., Sharma P. Interleukins and STAT signaling. Vitam. Horm. 2006, 74:165-206.
18. Yin T., Tsang M.L., Yang Y.C. JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes. J. Biol. Chem. 1994, 269:26614-26617.
19. Hirst S.J., Hallsworth M.P., Peng Q., Lee T.H. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain. Am. J. Respir. Crit. Care Med. 2002, 165:1161-1171.
20. Bendrups A., Hilton A., Meager A., Hamilton J.A. Reduction of tumor necrosis factor alpha and interleukin-1 beta levels in human synovial tissue by interleukin-4 and glucocorticoid. Rheumatol. Int. 1993, 12:217-220.
21. Niiro H., Otsuka T., Izuhara K., Yamaoka K., Ohshima K., Tanabe T., Hara S., Nemoto Y., Tanaka Y., Nakashima H., Niho Y. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood 1997, 89:1621-1628.
22. 2 production in human non-small cell lung cancer. Biochem. Biophys. Res. Commun. 2006, 343:995-1001.
23. Nemoto O., Yamada H., Kikuchi T., Shinmei M., Obata K., Sato H., Seiki M. Suppression of matrix metalloproteinase-3 synthesis by interleukin-4 in human articular chondrocytes. J. Rheumatol. 1997, 24:1774-1779.
24. Cawston T.E., Ellis A.J., Bigg H., Curry V., Lean E., Ward D. Interleukin-4 blocks the release of collagen fragments from bovine nasal cartilage treated with cytokines. Biochim. Biophys. Acta 1996, 1314:226-232.
25. Brinckmann R., Topp M.S., Zalan I., Heydeck D., Ludwig P., Kuhn H., Berdel W.E., Habenicht A.J.R. Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4. Biochem. J. 1996, 318:305-312.
26. Kayawickreme S.P., Gray T., Nettesheim P., Eling T. Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells. Am. J. Physiol. 1999, 276:L596-L603.
27. Shankaranarayanan P., Chaitidis P., Kuhn H., Nigam S. Acteylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J. Biol. Chem. 2001, 276:42753-42760.
28. Chen B., Tsui S., Boeglin W.E., Douglas R.S., Brash A.R., Smith T.J. Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves Disease. Evidence for anatomic site-selective actions of Th2 cytokines. J. Biol. Chem. 2006, 281:18296-18306.
29. Tong M., Ding Y., Tai H.H. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis 2006, 27:2170-2179.
30. 3H]prostaglandins and their use in the development of a simple and sensitive assay for 15-hydroxyprostaglandin dehydrogenase. Biochemistry 1976, 15:4586-4592.
31. +-dependent 15-hydroxyprostaglandin dehydrogenase in human promyelocytic leukaemia (HL-60) cells by phorbol ester. Biochem. J. 1991, 279:553-558.
32. Lin C.C., Tseng H.W., Hsieh H.L., Lee C.W., Wu C.Y., Cheng C.Y., Yang C.M. Tumor necrosis factor-alpha induces MMP-9 expression via p42/p44 MAPK, JNK, and nuclear factor-kappaB in A549 cells. Toxicol. Appl. Pharmacol. 2008, 229:386-398.
33. Liang K.C., Lee C.W., Lin W.N., Lin C.C., Wu C.B., Luo S.F., Yang C.M. Interleukin-1beta induces MMP-9 expression via p42/p44 MAPK, p38 MAPK, JNK, and nuclear factor-kappaB signaling pathways in human tracheal smooth muscle cells. J. Cell. Physiol. 2007, 211:759-770.
34. +-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G361-G368.
35. Cortes J.R., Perez G.M., Rivas M.D., Zamorano J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J. Immunol. 2007, 179:3881-3887.
36. 2 synthesis by interleukin-1beta is amplified by interferons but inhibited by interleukin-4 in human amnion-derived WISH cells. Biochim. Biophys. Acta 1996, 1310:48-52.
37. Shin C.Y., Lee W.J., Choi J.W., Choi M.S., Park G.H., Yoo B.K., Han S.Y., Ryu J.R., Choi E.Y., Ko K.H. Role of p38 MAPK on the down-regulation of matrix metalloproteinase-9 expression in rat astrocytes. Arch. Pharmacol. Res. 2007, 30:624-633.
38. Zhou X., Hu H., Huynh M.L., Kotaru C., Balzar S., Trudeau J.B., Wenzel S.E. Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. J. Allergy Clin. Immunol. 2007, 119:1388-1397.
39. Annabi B., Currie J.C., Moghrabi A., Béliveau R. Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk. Res. 2007, 31:1277-1284.
40. Cowden-Dahl K.D., Symowicz J., Ning Y., Gutierrez E., Fishman D.A., Adley B.P., Stack M.S., Hudson L.G. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res. 2008, 68:4606-4613.
41. Shin Y., Yoon S.H., Choe E.Y., Cho S.H., Woo C.H., Rho J.Y., Kim J.H. PMA-induced up-regulation of MMP-9 is regulated by a PKC alpha-NF-kappa B cascade in human lung epithelial cells. Exp. Mol. Med. 2007, 39:97-105.
42. Vinodhkumar R., Song Y.S., Ravikumar V., Ramakrishnan G., Devaki T. Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem. Biol. Interact. 2007, 165:220-229.
43. Chi X., Freeman B.M., Tong M., Zhao Y., Tai H.H. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch. Biochem. Biophys. 2009, 487:139-145.
44. Paul W.E. Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Found. Symp. 1997, 204:208-220.
45. Zamorano J., Wang H.Y., Wang L.M., Pierce J.H., Keegan A.D. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J. Immunol. 1996, 157:4926-4935.
46. Foltz I.N., Lee J.C., Young P.R., Schrader J.W. Hempoietic growth factors with the exception of Interleukin-4 activate the p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 1997, 272:3296-3301.
47. Foltz I.N., Schrader J.W. Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4. Blood 1997, 89:3092-3096.
48. Hunt A.E., Williams L.M., Lali F.V., Foxwell B.M.J. IL-4 regulation of p38 MAPK signaling is dependent on cell type. Cytokine 2002, 18:295-303.
49. Canfiled S., Lee Y., Schroder A., Rothman P. Cutting edge: IL-4 induces suppressor of cytokine signaling expression in B cells by a mechanism dependent on activation of p38 MAPK. J. Immunol. 2005, 174:2494-2498.
50. Pesu M., Aittomaki S., Takaluoma K., Lagerstedt A., Silvennoinen O. p38 mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription. J. Biol. Chem. 2002, 277:38254-38261.
51. Hirst S.J., Hallsworth M.P., Peng Q., Lee T. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1β and is mediated by the interleukin-4 receptor α chain. Am. J. Respir. Crit. Care Med. 2001, 165:1161-1171.
52. Lorentz A., Wilke M., Sellge G., Worthmann H., Klempnauer J., Manns M.P., Bischoff S.C. IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J. Immunol. 2005, 174:6751-6756.